Interventions for Extracranial Carotid Artery Stenosis: An Update
- 作者:Josephine F. Huang MD ; James F. Meschia MD
- 关键词:Carotid stenosis ; Carotid angioplasty and stenting ; Carotid endarterectomy ; Stroke prevention
- 刊名:Current Treatment Options in Cardiovascular Medicine
- 出版年:2016
- 出版时间:May 2016
- 年:2016
- 卷:18
- 期:5
- 全文大小:296 KB
- 参考文献:1.Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. New Engl J Med. 1991;325(7):445-53.
2.MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe (70-99%) or with mild (0–29%) carotid stenosis. European Carotid Surgery Trialists’ Collaborative Group. Lancet. 1991. 337(8752):1235-43.
3.Rothwell PM, Gutnikov SA, Warlow CP. Reanalysis of the final results of the European Carotid Surgery Trial. Stroke; J Cereb Circ. 2003;34(2):514–23.CrossRef
4.Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. JAMA. 1995;273(18):1421-8.
5.Eckstein HH et al. Results of the stent-protected angioplasty versus carotid endarterectomy (SPACE) study to treat symptomatic stenoses at 2 years: a multinational, prospective, randomised trial. Lancet Neurol. 2008;7(10):893–902.CrossRef PubMed
6.Mas JL et al. Endarterectomy versus angioplasty in patients with symptomatic severe carotid stenosis (EVA-3S) trial: results up to 4 years from a randomised, multicentre trial. Lancet Neurol. 2008;7(10):885–92.CrossRef PubMed
7.Brott TG et al. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med. 2010;363(1):11–23.CrossRef PubMed PubMedCentral
8.Silver FL et al. Safety of stenting and endarterectomy by symptomatic status in the Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST). Stroke; J Cereb Circ. 2011;42(3):675–80.CrossRef
9.Bruckert E et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients—cthe PRIMO study. Cardiovasc Drugs Ther / Int Soc Cardiovasc Pharmacother. 2005;19(6):403–14.CrossRef
10.Cohen JD et al. Understanding Statin use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol. 2012;6(3):208–15.CrossRef PubMed
11.Ucar M, Mjorndal T, Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf. 2000;22(6):441–57.CrossRef PubMed
12.Stroes ES et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015;36(17):1012–22.CrossRef PubMed PubMedCentral
13.Cannon CP, Blazing MA, Braunwald E. Ezetimibe plus a statin after acute coronary syndromes. N Engl J Med. 2015;373(15):1476–7.PubMed
14.Raal F et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation. 2012;126(20):2408–17.CrossRef PubMed
15.Sullivan D et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA. 2012;308(23):2497–506.CrossRef PubMed
16.Kohli P et al. Design and rationale of the LAPLACE-TIMI 57 trial: a phase II, double-blind, placebo-controlled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercholesterolemia on background statin therapy. Clin Cardiol. 2012;35(7):385–91.CrossRef PubMed PubMedCentral
17.Koren MJ et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2012;380(9858):1995–2006.CrossRef PubMed
18.Blom DJ et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014;370(19):1809–19.CrossRef PubMed
19.Robinson JG et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1489–99.CrossRef PubMed
20.Navarese EP et al. Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis. Ann Intern Med. 2015;163(1):40–51.CrossRef PubMed
21.Meschia JF et al. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke; J Cereb Circ. 2014;45(12):3754–832.CrossRef
22.Kernan WN et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke; J Cereb Circ. 2014;45(7):2160–236.CrossRef
23.Wright Jr JT et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103–16.CrossRef PubMed
24.Cushman WC et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1575–85.CrossRef PubMed
25.Abbott AL. Medical (nonsurgical) intervention alone is now best for prevention of stroke associated with asymptomatic severe carotid stenosis: results of a systematic review and analysis. Stroke; J Cereb Circ. 2009;40(10):e573–83.CrossRef
26.Spence JD et al. Effects of intensive medical therapy on microemboli and cardiovascular risk in asymptomatic carotid stenosis. Arch Neurol. 2010;67(2):180–6.CrossRef PubMed
27.Chimowitz MI et al. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med. 2011;365(11):993–1003.CrossRef PubMed PubMedCentral
28.Zaidat OO et al. Effect of a balloon-expandable intracranial stent vs medical therapy on risk of stroke in patients with symptomatic intracranial stenosis: the VISSIT randomized clinical trial. JAMA. 2015;313(12):1240–8.CrossRef PubMed
29.Munster AB et al. Temporal trends in safety of carotid endarterectomy in asymptomatic patients: systematic review. Neurology. 2015;85(4):365–72.CrossRef PubMed
30.Rerkasem K, Rothwell PM. Patch angioplasty versus primary closure for carotid endarterectomy. Cochrane Database Syst Rev. 2009;4:CD000160.PubMed
31.Heyer EJ et al. Statins reduce neurologic injury in asymptomatic carotid endarterectomy patients. Stroke; J Cereb Circ. 2013;44(4):1150–2.CrossRef
32.Naylor AR et al. Closing the loop: a 21-year audit of strategies for preventing stroke and death following carotid endarterectomy. Eur J Vasc Endovasc Surg : Off J Eur Soc Vasc Surg. 2013;46(2):161–70.CrossRef
33.Yadav JS et al. Protected carotid-artery stenting versus endarterectomy in high-risk patients. N Engl J Med. 2004;351(15):1493–501.CrossRef PubMed
34.•
Touze E et al. A clinical rule (sex, contralateral occlusion, age, and restenosis) to select patients for stenting versus carotid endarterectomy: systematic review of observational studies with validation in randomized trials. Stroke; J Cereb Circ. 2013;44(12):3394–400. The SCAR decision rule was validated with pooled data from SPACE, EVA-3S, and ICSS, and may be a useful tool in identifying patients who are at increased risk of CAS-related complications.CrossRef
35.Rothwell PM et al. Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. Lancet. 2004;363(9413):915–24.CrossRef PubMed
36.Rantner B, et al. The risk of carotid artery stenting compared with carotid endarterectomy is greatest in patients treated within 7 days of symptoms. J Vasc Surg. 2013;57(3):619-626 e2; discussion 625-6.
37.Voeks JH et al. Age and outcomes after carotid stenting and endarterectomy: the carotid revascularization endarterectomy versus stenting trial. Stroke; J Cereb Circ. 2011;42(12):3484–90.CrossRef
38.Bonati LH, Fraedrich G. Age modifies the relative risk of stenting versus endarterectomy for symptomatic carotid stenosis—a pooled analysis of EVA-3S, SPACE and ICSS. Eur J Vasc Endovasc Surg : Off J Eur Soc Vasc Surg. 2011;41(2):153–8.CrossRef
39.Voeks JH et al. Mediators of the Age Effect in the Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST). Stroke; J Cereb Circ. 2015;46(10):2868–73.CrossRef
40.Naggara O et al. Anatomical and technical factors associated with stroke or death during carotid angioplasty and stenting: results from the endarterectomy versus angioplasty in patients with symptomatic severe carotid stenosis (EVA-3S) trial and systematic review. Stroke; J Cereb Circ. 2011;42(2):380–8.CrossRef
41.Dumont TM et al. Understanding risk factors for perioperative ischemic events with carotid stenting: is patient age over 80 years or is unfavorable arch anatomy to blame? J Neurointerv Surg. 2014;6(3):219–24.CrossRef PubMed
42.••
Doig D, et al. Predictors of Stroke, Myocardial Infarction or Death within 30 Days of Carotid Artery Stenting: Results from the International Carotid Stenting Study. Eur J Vasc Endovasc Surg : the Off Jo Eur Soc Vasc Surg. 2015. Risk factors for stroke, MI, or death in patients enrolled in ICSS with symptomatic carotid stenosis >50% were investigated. There was an increased risk with increasing age, patients treated with open cell stent design, and in patients with atrial fibrillation. There was a decreased risk with current or former smokers, patients taking aspirin and clopidogrel prior to CAS, index event of amaurosis fugax, and right-sided procedures. The study highlights potential factors that may influence future risk-stratification of patients undergoing surgical carotid revascularization.
43.•
Ederle J et al. Effect of white-matter lesions on the risk of periprocedural stroke after carotid artery stenting versus endarterectomy in the International Carotid Stenting Study (ICSS): a prespecified analysis of data from a randomised trial. Lancet Neurol. 2013;12(9):866–72. The risk of all stroke or non-disabling stroke in patients with increased age-related white matter changes on preprocedural imaging was significantly higher in CAS-treated patients when compared to patients with less white matter changes. This was not seen in the CEA-treated patients, and suggests that preprocedural imaging can be useful in risk stratification of patients being considered for CAS.CrossRef PubMed PubMedCentral
44.Schnaudigel S et al. New brain lesions after carotid stenting versus carotid endarterectomy: a systematic review of the literature. Stroke; J Cereb Circ. 2008;39(6):1911–9.CrossRef
45.Bijuklic K et al. The PROFI study (Prevention of Cerebral Embolization by Proximal Balloon Occlusion Compared to Filter Protection During Carotid Artery Stenting): a prospective randomized trial. J Am Coll Cardiol. 2012;59(15):1383–9.CrossRef PubMed
46.Montorsi P et al. Microembolization during carotid artery stenting in patients with high-risk, lipid-rich plaque. A randomized trial of proximal versus distal cerebral protection. J Am Coll Cardiol. 2011;58(16):1656–63.CrossRef PubMed
47.Cano MN et al. Randomized comparison of distal and proximal cerebral protection during carotid artery stenting. J Am Coll Cardiol Intv. 2013;6(11):1203–9.CrossRef
48.Giri J et al. Proximal versus distal embolic protection for carotid artery stenting: a national cardiovascular data registry analysis. J Am Coll Cardiol Intv. 2015;8(4):609–15.CrossRef
49.Hart JP, et al. Do device characteristics impact outcome in carotid artery stenting? J Vasc Surg. 2006. 44(4):725-30; discussion 730-1.
50.Bosiers M, et al. Does free cell area influence the outcome in carotid artery stenting? Eur J Vasc Endovasc Surg : Off J Eur Soc Vasc Surg. 2007;33(2): p. 135-41; discussion 142-3.
51.Maleux G et al. Outcome of carotid artery stenting at 2 years follow-up: comparison of nitinol open cell versus stainless steel closed cell stent design. J Cardiovasc Surg. 2009;50(5):669–75.
52.Timaran CH, et al. Randomized clinical trial of open-cell vs closed-cell stents for carotid stenting and effects of stent design on cerebral embolization. J Vasc Surg. 2011;54(5):1310-1316 e1; discussion 1316.
53.Kwolek CJ et al. Results of the ROADSTER multicenter trial of transcarotid stenting with dynamic flow reversal. J Vasc Surg. 2015;62(5):1227–1234 e1.CrossRef PubMed
作者单位:Josephine F. Huang MD (1)
James F. Meschia MD (1)
1. The Department of Neurology (JFH, JFM), Mayo Clinic Florida, 4500 San Pablo Road, Jacksonville, FL, 32224, USA
刊物主题:Cardiology;出版者:Springer USISSN:1534-3189